Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma

Sun-Ha BOO; Joo-Hyun O; Soo-Jin KWON; Ie-Ryung YOO; Sung-Hoon KIM; Gyeong-Sin PARK; Byung-Ock CHOI; Seung-Eun JUNG; Seok-Goo CHO.
Korean Journal of Nuclear Medicine ; : 263-269, 2019.
Artículo en Inglés | WPRIM | ID: wpr-997420

Documentos relacionados

  1. Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma
  2. Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma.
  3. Prognostic Impact of Pretreatment 2-[<sup>18</sup>F]-FDG PET/CT Parameters in Primary Gastric DLBCL.
  4. Combined prognostic role of TARC and interim <sup>18</sup>F-FDG PET/CT in patients with Hodgkin lymphoma-real world observational study.
  5. Pretreatment <sup>18</sup>F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
  6. Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
  7. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
  8. The Potential Prognostic Value of Dual-Imaging PET Parameters Based on <sup>18</sup>F-FDG and <sup>18</sup>F-OC for Neuroendocrine Neoplasms.
  9. Prognostic significance of 18F-Fluorodeoxyglucose positron-emission tomography parameters in patients with biliary tract cancers: a meta-analysis.
  10. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.